AstraZeneca PLC (AZN)vsPark Dental Partners, Inc. Common Stock (PARK)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
PARK
Park Dental Partners, Inc. Common Stock
$20.59
-3.29%
HEALTHCARE · Cap: $97.15M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 24313% more annual revenue ($61.37B vs $251.37M). AZN leads profitability with a 17.0% profit margin vs -1.4%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PARK
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for PARK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Generating 2.2B in free cash flow
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 1.9%
Weak financial health signals
ROE of -18.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PARK
The strongest argument for PARK centers on Free Cash Flow.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PARK
The primary concerns for PARK are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.02 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PARK is a turnaround play — different risk/reward profiles.
AZN is growing revenue faster at 6.4% — sustainability is the question.
PARK generates stronger free cash flow (2.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 28/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Park Dental Partners, Inc. Common Stock
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Park Dental Partners, Inc. is a dental resource organization that offers business support services to dentists throughout Minnesota and Wisconsin. The company is headquartered in Roseville, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?